BrightSpring Health Services, Inc. (BTSG)
| Market Cap | 12.52B +83.0% |
| Revenue (ttm) | 14.37B +26.4% |
| Net Income | 365.97M +458.6% |
| EPS | 1.64 +400.0% |
| Shares Out | 208.32M |
| PE Ratio | 36.70 |
| Forward PE | 29.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,781,910 |
| Open | 60.76 |
| Previous Close | 60.86 |
| Day's Range | 59.77 - 61.00 |
| 52-Week Range | 30.64 - 73.75 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 78.94 (+31.33%) |
| Earnings Date | Oct 30, 2026 |
About BTSG
BrightSpring Health Services, Inc. operates as a home and community-based healthcare services platform in the United States. The company operates through two segments, Pharmacy Solutions and Provider Services. Its platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It also offers infused, injectable, and oral medication services; and patient-centric, highly skilled, and compassionate clinical home health care, as well... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for BTSG stock is "Strong Buy." The 12-month stock price target is $78.94, which is an increase of 31.33% from the latest price.
News
BrightSpring Health Services, Inc. to Announce Third Quarter 2026 Financial Results on October 30, 2026
LOUISVILLE, Ky., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its third quarter 2026 f...
BrightSpring Health Services Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
The forum highlighted integrated growth strategies across pharmacy and provider services, driven by operational synergies, targeted M&A, and technology investments. Specialty pharmacy and home health are key growth areas, with AI initiatives enhancing efficiency and future commercial potential.
BrightSpring Health Services Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Raised 2026 EBITDA guidance on strong volume and margin gains, with specialty pharmacy and provider segments driving growth. LDD pipeline and recent drug launches support future expansion, while efficiency initiatives offset IRA headwinds. M&A activity remains robust, with integration of Amedisys ahead of plan.
BrightSpring Health Services Transcript: 2026 Jefferies Healthcare Services and Technology Conference
Strong performance continues across pharmacy and provider businesses, with double-digit growth driven by generics, LDDs, and ongoing innovation. Disciplined M&A, robust cash flow, and technology investments support a 15%–20% EBITDA growth target over the next two years.
BrightSpring Health Services Transcript: Wells Fargo 21st Annual Healthcare Conference
Pharmacy growth is supported by LDD ramps, generic conversions, infusion volume and operational efficiencies; IRA mitigation reduced the 2026 EBITDA impact to $15 million. Provider growth, AI investment and disciplined M&A remain central priorities, with potential buybacks to be revisited in 9-12 months.
BrightSpring Health price target raised to $70 from $60 at Deutsche Bank
Deutsche Bank raised the firm’s price target on BrightSpring Health (BTSG) to $70 from $60 and keeps a Buy rating on the shares.
BrightSpring Health selloff appears overdone, says Mizuho
Mizuho reiterated an Outperform rating and $86 price target on BrightSpring Health (BTSG), noting the stock is down sharply following Q2 results as investors focus on gross margin performance within…
BrightSpring Health Services Earnings Call Transcript: Q2 2026
Q2 2026 saw 23% revenue growth and 44% adjusted EBITDA growth, driven by strong performance in both Pharmacy Solutions and Provider Services. Guidance for 2026 was raised, with continued investments in technology, M&A, and operational efficiency, despite IRA headwinds.
BrightSpring Health Services Earnings release: Q2 2026
BrightSpring Health Services released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
BrightSpring Health Services Slides: Q2 2026
BrightSpring Health Services has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 31, 2026.
BrightSpring Health Services Quarterly report: Q2 2026
BrightSpring Health Services has published its Q2 2026 quarterly earnings report on July 31, 2026.
BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance
LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services f...
BrightSpring Health to replace Chart Industries in S&P 400 at open on 7/17
17:18 EDT BrightSpring Health (BTSG) to replace Chart Industries (GTLS) in S&P 400 at open on 7/17
BrightSpring Health price target raised to $80 from $71 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BrightSpring Health (BTSG) to $80 from $71 and keeps an Overweight rating on the shares. BrightSpring continues to execute well, with expectations…
BrightSpring Health price target raised to $80 from $60 at KeyBanc
KeyBanc raised the firm’s price target on BrightSpring Health (BTSG) to $80 from $60 and keeps an Overweight rating on the shares. Healthcare utilization continued to moderate through the first…
BrightSpring Health price target raised to $78 from $61 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on BrightSpring Health (BTSG) to $78 from $61 and keeps an Overweight rating on the shares. The firm’s outlook for…
Guggenheim starts ‘well positioned’ BrightSpring Health with a Buy
As previously reported, Guggenheim initiated coverage of BrightSpring Health (BTSG) with a Buy rating and $81 price target BrightSpring is well positioned to capitalize on secular tailwinds in healthc...
BrightSpring Health initiated with a Buy at Guggenheim
Guggenheim initiated coverage of BrightSpring Health (BTSG) with a Buy rating and $81 price target
BrightSpring Health initiated with an Outperform at Raymond James
Raymond James analyst Parker Snure initiated coverage of BrightSpring Health (BTSG) with an Outperform rating and $80 price target
Raymond James starts BrightSpring Health at Outperform on ‘durable growth’
Raymond James initiated coverage of BrightSpring Health (BTSG) with an Outperform rating and $80 price target The firm sees the stock as a durable growth story with potential upside to…
BrightSpring Health Services, Inc. to Announce Second Quarter 2026 Financial Results on July 31, 2026
LOUISVILLE, Ky., July 08, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its second quarter 2026 ...
BrightSpring Health price target raised to $85 from $63 at UBS
UBS raised the firm’s price target on BrightSpring Health (BTSG) to $85 from $63 and keeps a Buy rating on the shares.
BrightSpring Health price target raised to $77 from $66 at BofA
BofA raised the firm’s price target on BrightSpring Health (BTSG) to $77 from $66 and keeps a Buy rating on the shares. The proposed 2027 Medicare rate update for home…
BrightSpring Health price target raised to $90 from $65 at BTIG
BTIG analyst David Larsen raised the firm’s price target on BrightSpring Health (BTSG) to $90 from $65 and keeps a Buy rating on the shares following management comments at recent…
BrightSpring Health price target raised to $81 from $65 at TD Cowen
TD Cowen raised the firm’s price target on BrightSpring Health (BTSG) to $81 from $65 and keeps a Buy rating on the shares. The firm called it its Our Best…